BioLine Rx (BLRX) Stock Price, Quote, News & History | Benzinga

SPY776.37 QQQ754.29−0.71%BTC/USD83,602.43−2.27%DIA511.65 GLD377.58 TLT76.58−0.91%

BioLine Rx Ltd (BLRX) Stock Price, Quote, News & History

BLRXNASDAQ

Trade with Public

Trade with Public

$2.34

0.020.86%

Last update: Oct 1, 4:01 AM

$2.41

0.093.88%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Options Stock Report

Key Statistics

Open

-

Close

$2.34

Volume / Avg.

0 / 19.25K

Day Range

- - -

52 Wk Range

2.15 - 4.56

Market Cap

$12.00M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

2.93%

Days to Cover

6.05

Recent BioLine RX Ltd News

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.

Vandana Singh

Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings

BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.

Avi Kapoor

3 Stocks Getting Rare Double Upgrades From Analysts

Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts’ expectations. However, that can become an opportunity for nimble investors with some cash on

MarketBeat

Dow Edges Higher; Dell Shares Fall After Q1 Results

Avi Kapoor

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-10.80M

Investing Cash Flow (TTM)

12.39M

Financing Cash Flow (TTM)

-4.49M

Free Cash Flow (TTM)

-10.83M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-2.90M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.60M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.27

PB Ratio (TTM)

0.83

Earnings Yield % (TTM)

0.00%

Earnings Yield % (FWD)

-54.78%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.77

Company Debt

Total Debt

$6.70M

LT Debt

$2.22M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$374.00K

Total Cash

$4.63M

Debt to Equity

0.58

Issuance of Debt (TTM)

-$374.00K

Repayment of Debt (TTM)

-$4.87M